Watson Announces Silodosin NDA Accepted For Filing By FDA For The Treatment Of Benign Prostatic Hyperplasia Part 2
⊆ December 7th, 2008 by artichelea78 | ˜ No Comments »The complex be originally mechanized with Kissei Pharmaceutical Co., Ltd., contained by Japan and licensed to Watson in favour of the United States, Canada and Mexico. Kissei exultantly launch Urief(R) (silodosin) in Japan in May of 2006 at a two times all afternoon dose of 4mg. Urief(R) be bazaar in conciliation beside Daiichi Sankyo Pharmaceutical Co., Ltd.
BPH, or an enlarged prostate, is a stipulation found individual in man and is characterized by a non-cancerous escalation of the prostate gland. Symptoms of BPH brood over urinary intricacy, urinary frequency and an inability to implement bladder not taken. The numeral of BPH patients have be snowballing with the augmentation of the elderly population. In the United States, BPH affect higher than partially of men in their 60’s and in place of copious as 90 percent of men by the age of 85. According to IMS facts, BPH symptom be the original aim patients visit their urologists in 2006.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a prime specialty pharmaceutical managing that get it together, manufacture, market, deal in and distributes heap scorn on and generic pharmaceutical products. Watson pursue a distension strategy unite central merchandise increase, strategic alliances and collaboration and synergistic acquisition of products and company.
Watson is committed to providing ahead of its time treatment in urology fastidiousness. With seven products in a minute unclaimed to address provisos range from overactive bladder to prostate cancer, Watson keep alive to benefaction research that not only gratification the symptoms associated with urological conditions, but that aid trade name urology patients’ live more livable. The Watson portfolio in the U.S. include Oxytrol(R); Trelstar(R) LA; Trelstar(R) Depot; Androderm(R); AndroGel(R), underneath a co-promotion agreement with Solvay Pharmaceuticals, Inc.; and ProQuin(R) XR, under a co-promotion agreement with Depomed, Inc. In fixture to silodosin, the Watson urology portfolio includes various products under development; Uracyst(R), for the healing of interstitial cystitis; a six-month formulation of Trelstar(R) (triptorelin pamoate for injectable suspension), for the treatment of advanced prostate cancer; and oxybutynin topical gel, for overactive bladder.
All tablets can find here zanaflex 4 mg
Read more about ultram
medecine women’s health blogs other
